Royalty Pharma (RPRX) Stock Statistics & Valuation Metrics

Royalty Pharma has a market cap or net worth of $25.79B. The enterprise value is $18.74B.

Royalty Pharma has 427,247,500 shares outstanding. The number of shares has decreased by -2.65% in one year.

Royalty Pharma’s return on equity (ROE) is 0.08 and return on invested capital (ROIC) is 5.21%.

The current PE Ratio of Royalty Pharma is 25.1. Royalty Pharma’s PEG ratio is -3.26.

In the last 12 months, Royalty Pharma had revenue of 2.38B and earned 770.95M in profits. Earnings per share was 1.79.

In the last 12 months, operating cash flow was 2.41B and capital expenditures 1.11M, giving a free cash flow of 2.41B billion.

Royalty Pharma pays an annual dividend of $0.22, resulting in a dividend yield of 2.23%

Royalty Pharma upcoming earnings date is May 7, 2026, Before Open (Confirmed).

Royalty Pharma as a current ratio of 0.97, with Debt / Equity ratio of 0.00%

In the past 12 months, Royalty Pharma has paid 553.25M in taxes.

Royalty Pharma EV to EBITDA ratio is 15.99, with an EV/FCF ratio of 10.02.

Royalty Pharma has $955.04M in cash and marketable securities with $8.97B in debt, giving a net cash position of -$8.01B billion.

Gross margin is 73.85%, with operating margin of 65.58%, and net profit margin of 32.42%.

The average price target for Royalty Pharma is $51.43, which is 11.43% higher than the current price. The consensus rating is Strong Buy